Stefano Menzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4514304/publications.pdf

Version: 2024-02-01

58 2,383 23 47 papers citations h-index g-index

61 61 61 2585
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Visceral fat inflammation and fat embolism are associated with lung \hat{a} € Ms lipidic hyaline membranes in subjects with COVID-19. International Journal of Obesity, 2022, 46, 1009-1017.	3.4	22
2	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. Scientific Reports, 2022, 12, 5736.	3.3	6
3	Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021. Virology Journal, 2021, 18, 168.	3.4	36
4	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. Vaccines, 2021, 9, 1124.	4.4	3
5	Quantification of the HIV-1 total reservoir in the peripheral blood of $na\tilde{A}^-$ ve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. Clinical Chemistry and Laboratory Medicine, 2021, 59, 609-617.	2.3	1
6	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. Digestive and Liver Disease, 2020, 52, 434-439.	0.9	4
7	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. Viruses, 2020, 12, 798.	3.3	46
8	Trend of clinical vancomycin-resistant enterococci isolated in a regional Italian hospital from 2001 to 2018. Brazilian Journal of Microbiology, 2020, 51, 1607-1613.	2.0	5
9	Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing. Genes, 2020, 11, 929.	2.4	27
10	First Detection of SARS-CoV-2 by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay in Pleural Fluid. Chest, 2020, 158, e143-e146.	0.8	26
11	Antimicrobial Resistance: A Challenge for the Future. , 2020, , 13-29.		3
12	Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment. Genes, 2018, 9, 293.	2.4	7
13	Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002–2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment. Antiviral Research, 2017, 143, 62-68.	4.1	6
14	Hepatitis E in a region of Italy: An emerging autochthonous infection?. Digestive and Liver Disease, 2016, 48, 1340-1345.	0.9	11
15	Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes. Hepatitis Monthly, 2016, 16, e28751.	0.2	3
16	A Large Epidemic of Hepatitis B in Serbia: An Integrated Model for Outbreak Investigations in Healthcare Settings. Infection Control and Hospital Epidemiology, 2014, 35, 732-735.	1.8	1
17	Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. Antiviral Therapy, 2013, 19, 201-209.	1.0	9
18	<i>No pol</i> mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. Journal of Medical Virology, 2011, 83, 391-398.	5.0	1

#	Article	IF	CITATIONS
19	Hemagglutinin 222 Variants in Pandemic (H1N1) 2009 Virus. Emerging Infectious Diseases, 2011, 17, 749-751.	4.3	8
20	Insulinâ€ike growth factor 1 expression correlates with clinical outcome in Kâ€RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	5.1	67
21	Absence of Neuroinvasive Disease in a Liver Transplant Recipient Who Acquired West Nile Virus (WNV) Infection from the Organ Donor and Who Received WNV Antibodies Prophylactically. Clinical Infectious Diseases, 2010, 51, e34-e37.	5.8	47
22	Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic PLOS Currents, 2010, 2, RRN1149.	1.4	18
23	Lowâ€Abundance Drug Resistance Mutations: Extending the HIV Paradigm to Hepatitis B Virus. Journal of Infectious Diseases, 2009, 200, 1798-1799.	4.0	8
24	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. Journal of Antimicrobial Chemotherapy, 2009, 64, 616-624.	3.0	34
25	Surgery and topic cidofovir for nasal squamous papillomatosis in HIV+ patient. European Archives of Oto-Rhino-Laryngology, 2009, 266, 937-939.	1.6	7
26	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antiviral Therapy, 2009, 14, 359-369.	1.0	14
27	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. Journal of Medical Virology, 2008, 80, 201-208.	5.0	17
28	Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiology, 2008, 8, 112.	3.3	21
29	Determinants of HIV-1 Genotypic Resistance to Darunavir (TMC114) in a Large Italian Resistance Database (Antiretroviral Resistance Cohort Analysis). Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 373-375.	2.1	1
30	Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: No evidence ofBorrelia burgdorferiassociation. Leukemia and Lymphoma, 2007, 48, 2184-2188.	1.3	40
31	Molecular and cellular determinants of cellâ€toâ€cell transmission of HCV in vitro. Journal of Medical Virology, 2007, 79, 1491-1499.	5.0	12
32	Human papillomavirus infections: new perspectives for prevention and treatment. New Microbiologica, 2007, 30, 189-212.	0.1	6
33	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). Aids, 2006, 20, 795-803.	2.2	139
34	Frequency and Treatmentâ€Related Predictors of Thymidineâ€Analogue Mutation Patterns in HIVâ€1 Isolates after Unsuccessful Antiretroviral Therapy. Journal of Infectious Diseases, 2006, 193, 1219-1222.	4.0	26
35	Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrobial Agents and Chemotherapy, 2004, 48, 3253-3259.	3.2	83
36	Distribution and molecular analysis of mef(A)-containing elements in tetracycline-susceptible and -resistant Streptococcus pyogenes clinical isolates with efflux-mediated erythromycin resistance. Journal of Antimicrobial Chemotherapy, 2004, 54, 991-998.	3.0	57

#	Article	IF	Citations
37	Genotypic and Phenotypic Correlates of the HIV Type 1envGene Evolution in Infected Children with Discordant Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 1306-1313.	1.1	14
38	Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones. Virology, 2003, 307, 328-340.	2.4	16
39	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2003, 51, 135-139.	3.0	10
40	Processivity and drug-dependence of HIV-1 protease. Aids, 2003, 17, 663-671.	2.2	31
41	Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. Aids, 2003, 17, 663-71.	2.2	9
42	Inhibition of R5X4 Dualtropic HIV-1 Primary Isolates by Single Chemokine Co-receptor Ligands. Virology, 2001, 280, 253-261.	2.4	19
43	Identification of Six Putative Novel Human Papillomaviruses (HPV) and Characterization of Candidate HPV Type 87. Journal of Virology, 2001, 75, 11913-11919.	3.4	22
44	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. Aids, 2000, 14, 1101-1110.	2.2	13
45	Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1 <i>env</i> Gene Evolution. Journal of Virology, 1999, 73, 3764-3777.	3.4	34
46	Rare mutations in a domain crucial for V3-loopstructure prevail in replicating HIV from long-term non-progressors. Aids, 1998, 12, 985-997.	2.2	27
47	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 209-216.	27.0	717
48	Competitive polymerase chain reaction and analysis of viral activity at the molecular level. Genetic Analysis, Techniques and Applications, 1994, 11, 1-6.	1.5	24
49	Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. Molecular and Cellular Probes, 1994, 8, 229-234.	2.1	38
50	Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product. Virology, 1993, 196, 878-882.	2.4	68
51	Clearance of HIV-1 viraemia after seroconversion. Lancet, The, 1993, 341, 315-316.	13.7	21
52	A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. Gene, 1992, 122, 313-320.	2.2	260
53	A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. Virology, 1992, 186, 133-147.	2.4	94
54	Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. Virology, 1992, 188, 890-895.	2.4	29

STEFANO MENZO

#	Article	IF	CITATION
55	Lack of detectable human T-cell lymphotropic virus type I sequences in samples from multiple sclerosis patients. Journal of Medical Virology, 1992, 36, 155-161.	5.0	9
56	A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. Journal of Virological Methods, 1991, 32, 245-253.	2.1	25
57	Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. Journal of Virological Methods, 1991, 32, 31-39.	2.1	24
58	Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. Journal of Medical Virology, 1991, 34, 89-95.	5.0	49